Cost-effectiveness analysis of HIV/AIDS “Test and treat” strategy vs. Current treatment guideline in Botswana
Cost-effectiveness analysis of HIV/AIDS “Test and treat” strategy vs. Current treatment guideline in Botswana

Author: Geffrey Li

Publisher: GRIN Verlag

Published: 2015-03-17

Total Pages: 24

ISBN-13: 3656921644

DOWNLOAD EBOOK

Seminar paper from the year 2015 in the subject Medicine - Other, Johns Hopkins University, language: English, abstract: A more aggressive strategy “test and treat” is predicted to reduce AIDS-related mortality, increase the life expectancy of people living with HIV and is cost-effective. However, the cost-effectiveness studies related to “test and treat” strategy did not consider the possibility of increased drug resistance due to poor adherence, which is not rare in developing countries. There is a need for a cost-effectiveness analysis related to “test and treat” strategy in developing countries that includes drug resistance as an important parameter. This analysis is to support the government of Botswana to examine the cost-effectiveness of a HIV/AIDS “test and treat” strategy vs. current treatment guideline, which is providing treatment to patients with a CD4 count of

Disease Control Priorities, Third Edition (Volume 6)
Disease Control Priorities, Third Edition (Volume 6)

Author: King K. Holmes

Publisher: World Bank Publications

Published: 2017-11-06

Total Pages: 1027

ISBN-13: 1464805253

DOWNLOAD EBOOK

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection
Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection

Author: World Health Organization

Publisher:

Published: 2016

Total Pages: 429

ISBN-13: 9789241549684

DOWNLOAD EBOOK

These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.

Preventing and Mitigating AIDS in Sub-Saharan Africa
Preventing and Mitigating AIDS in Sub-Saharan Africa

Author: National Research Council (U.S.). Panel on Data and Research Priorities for Arresting AIDS in Sub-Saharan Africa

Publisher: National Academies

Published: 1996-01-01

Total Pages: 36

ISBN-13:

DOWNLOAD EBOOK

The AIDS epidemic in Sub-Saharan Africa continues to affect all facets of life throughout the subcontinent. Deaths related to AIDS have driven down the life expectancy rate of residents in Zambia, Kenya, and Uganda with far-reaching implications. This book details the current state of the AIDS epidemic in Africa and what is known about the behaviors that contribute to the transmission of the HIV infection. It lays out what research is needed and what is necessary to design more effective prevention programs.

Guidelines on the Management of Latent Tuberculosis Infection
Guidelines on the Management of Latent Tuberculosis Infection

Author: WHO

Publisher: World Health Organization

Published: 2015-01-15

Total Pages: 38

ISBN-13: 9241548908

DOWNLOAD EBOOK

BACKGROUND: Latent tuberculosis infection (LTBI), defined as a state of persistent immune response to prior-acquired Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB, affects about one-third of the world's population. Approximately 10% of people with LTBI will develop active TB disease in their lifetime, with the majority developing it within the first five years after initial infection. Currently available treatments have an efficacy ranging from 60% to 90%. Systematic testing and treatment of LTBI in at-risk populations is a critical component of WHO's eight-point framework adapted from the End TB Strategy to target pre-elimination and, ultimately, elimination in low incidence countries. OVERVIEW: Recognizing the importance of expanding the response to LTBI, in 2014 WHO developed Guidelines on the Management of Latent Tuberculosis Infection. The guidelines are primarily targeted at high-income or upper middle-income countries with an estimated TB incidence rate of less than 100 per 100 000 population, because they are most likely to benefit from it due to their current TB epidemiology and resource availability. The overall objective of the guidelines is to provide public health approach guidance on evidence-based practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. Specific objectives include identifying and prioritizing at-risk population groups for targeted intervention of LTBI testing and treatment, including defining an algorithm, and recommending specific treatment options. The guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management based on available resources, epidemiology of TB including intensity of transmission, the health-care delivery system of the country, and other national and local determinants.

A Guide to the Clinical Care of Women with HIV
A Guide to the Clinical Care of Women with HIV

Author: Jean R. Anderson

Publisher: DIANE Publishing Inc.

Published: 2005

Total Pages: 636

ISBN-13: 9780160726118

DOWNLOAD EBOOK

NOTE: NO FURTHER DISCOUNT FOR THIS PRODUCT ITEM -OVERSRTOCK SALE-- Significantly reduced price. Edited by Jean R. Anderson. This guide addresses the health care needs unique to women with HIV. It targets clinicians who provide primary care to women as well as those seeking an understanding of how to take care of women with HIV/AIDS. This guide includes tables, figures, color plates, resources, references, and indices. This 2005 edition includes new chapters on international issues and nutrition. Edge indexed."

Disease Control Priorities in Developing Countries
Disease Control Priorities in Developing Countries

Author: Dean T. Jamison

Publisher: World Bank Publications

Published: 2006-04-02

Total Pages: 1449

ISBN-13: 0821361805

DOWNLOAD EBOOK

Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries.

Guidelines on Hepatitis B and C Testing
Guidelines on Hepatitis B and C Testing

Author: World Health Organization

Publisher: World Health Organization

Published: 2017

Total Pages: 0

ISBN-13: 9789241549981

DOWNLOAD EBOOK

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

Global AIDS Monitoring 2019
Global AIDS Monitoring 2019

Author: United Nations Publications

Publisher: UN

Published: 2019-04-17

Total Pages: 202

ISBN-13: 9789292530884

DOWNLOAD EBOOK

The purpose of this document is to provide guidance to national AIDS programmes and partners on the use of indicators to measure and report on the country response. The 2016 United Nations Political Declaration on Ending AIDS, adopted at the United Nations General Assembly High-Level Meeting on AIDS in June 2016, mandated UNAIDS to support countries in reporting on the commitments in the Political Declaration. The Political Declaration on Ending AIDS built on three previous political declarations: the 2001 Declaration of Commitment on HIV/AIDS, the 2006 Political Declaration on HIV/AIDS and the 2011 Political Declaration on HIV and AIDS.

WHO consolidated guidelines on drug-resistant tuberculosis treatment
WHO consolidated guidelines on drug-resistant tuberculosis treatment

Author: World Health Organization

Publisher: World Health Organization

Published: 2018-11-07

Total Pages: 0

ISBN-13: 9789241550529

DOWNLOAD EBOOK

Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to treat than drug-susceptible ones, and threaten global progress towards the targets set by the End TB Strategy of the World Health Organization (WHO). There is thus a critical need for evidence-based policy recommendations on the treatment and care of patients with DR-TB, based on the most recent and comprehensive evidence available. In this regard, the WHO consolidated guidelines on drug-resistant tuberculosis treatment fulfil the mandate of WHO to inform health professionals in Member States on how to improve treatment and care for patients with DR-TB. Between 2011 and 2018, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update, issued by WHO in December 2018. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups (GDGs), using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.